SCHEDULE: Jorey Chernett Discloses 5.4% Stake in EXAGEN INC.

Jorey Chernett has reported beneficial ownership of 5.4% of EXAGEN INC.'s common stock, totaling 1,231,438 shares, as of January 30, 2026.

Summary

• Jorey Chernett beneficially owns 1,231,438 shares of EXAGEN INC. common stock.
• This ownership represents 5.4% of the total class of securities.
• Chernett holds sole voting power over 1,231,438 shares and sole dispositive power over 1,231,438 shares.
• The filing is a Schedule 13G, indicating a passive investment intent, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant individual investor has taken a substantial passive stake in EXAGEN INC., potentially signaling confidence in the company's valuation or future prospects.

Positives

• A significant individual investor, Jorey Chernett, has taken a 5.4% stake in EXAGEN INC., potentially signaling confidence in the company's future prospects.
• The filing indicates a passive investment, suggesting no immediate intent to influence control of the issuer, which can be viewed as a stable long-term interest.

Future Outlook

No forward-looking statements or guidance regarding EXAGEN INC.'s operations or financial performance are provided in this beneficial ownership disclosure.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for investors acquiring more than 5% of a company's stock with passive intent. This filing indicates an individual investor's belief in EXAGEN INC.'s long-term prospects without seeking active management influence, aligning with typical passive investment strategies in the biotech or diagnostic industry.

Comparison to Industry Standards

• This filing is a standard disclosure of a significant passive stake, common across various industries for investors crossing the 5% ownership threshold. No specific comparable companies, projects, or results are mentioned within the filing itself.

Stakeholder Impact

• Shareholders: May view the new significant investor as a positive sign of confidence in EXAGEN INC.'s value proposition, potentially influencing market sentiment positively.

Key Dates

Recommendation

The disclosure of a new 5.4% passive stake by Jorey Chernett in EXAGEN INC. is a positive indicator of investor confidence. However, without additional operational or financial updates, a 'hold' recommendation is appropriate, suggesting investors monitor future company performance and Chernett's continued involvement.

Keywords

EXAGEN INC., Jorey Chernett, Schedule 13G, beneficial ownership, common stock, passive investment, institutional investor